Veralto Corporation (NYSE: VLTO) — The Moat Holds; Deal Discipline Must Prove It

Published: 2026-09-11 · Verdict: Hold · Entry price: $85 · Price target: $105 · Research confidence: High (85%)

Executive conclusion

Analyst Take

HOLD at $93.45; preferred entry at or below $85; 12-month base-case value $105. Veralto remains an unusually good industrial franchise, but the investment case is no longer mainly about recognizing the quality of a neglected Danaher spin. The quality is visible: 62.2% of first-half 2026 revenue was classified as recurring, trailing revenue was approximately $5.70 billion, gross margin exceeded 60%, trailing standardized ROIC was about 18%, and first-half free cash flow of $498 million slightly exceeded net income. Capex remains near 1% of sales. Those results are consistent with valuable installed bases, proprietary consumables, application expertise and customer workflows at Hach, Videojet and selected other brands. They are not consistent with a commodity-equipment vendor. [S1][S2][S11]

The operating evidence is nevertheless more mixed than the headline 4.2% Q2 core growth suggests. First-half core growth was 3.1%, including approximately 2.4 points of price, leaving only 0.7 points of implied volume and mix. Q2 improved to roughly 1.2 points of implied volume/mix, but the improvement was not broad. Water Quality delivered 5.7% core growth with 2.9 points of price, while PQI delivered 2.0% core growth against approximately 3.0 points of price—implying continued volume/mix contraction. Within Water Quality, ChemTreat grew 10.7% in Q2 while analytics grew 2.8%. Management expects second-half core growth of 5–6% led by volume, but that is a forecast, not reported performance. The next two quarters will therefore determine whether Veralto is moving from price-supported resilience to genuine demand acceleration. [S2][S3][S12]

Capital allocation is now the load-bearing issue. Veralto deployed $620 million on acquisitions and $434 million on repurchases in the first half, subsequently acquired Alfaa UV, and agreed to pay $465 million for Cleanwater1. Cleanwater1’s tax-adjusted price is approximately 17 times trailing adjusted EBITDA, excludes prospective synergies, and supports a disclosed objective of only reaching or exceeding WACC by year four. GlobalVision and In-Situ were also priced using synergy-inclusive EBITDA and have three-to-five-year return timelines; TraceGains carried a year-six double-digit-return objective. These businesses fit Veralto’s strategic filters, but fit is not return. [S5][S6][S7][S8][S9]

The strongest adverse audit finding concerns incentives. The proxy emphasizes adjusted EPS, core growth, cash conversion and relative TSR, with ROIC only a plus-or-minus 10% PSU modifier. More importantly, the proxy’s adjusted-invested-capital definition excludes qualifying acquisitions of at least $250 million completed during the performance period. That means the largest acquisition decisions may not immediately burden the compensation measure intended to protect returns. This does not prove poor behavior, but it invalidates the prior report’s claim that the compensation design was strong evidence against expensive empire building. [S4]

At the current price, VLTO trades at approximately 21.3 times the $4.39 midpoint of management’s 2026 adjusted-EPS guidance, about 23.6 times trailing GAAP EPS, an estimated 17.3 times trailing EBITDA, and a roughly 4.5% trailing free-cash-flow yield. That is fair for a durable mid-single-digit compounder, but it leaves limited room for a volume disappointment or gradual ROIC dilution. The base case assumes approximately 4.5–5% organic growth, modest normalized margin expansion, disciplined integration and high-single-digit-to-low-double-digit per-share growth. The strongest bull case is that Water Quality volume, PQI recovery and restructuring benefits lift the durable growth algorithm. The strongest bear case is that price, buybacks and exclusions obscure a roughly 3% volume-light business while acquisitions earn only around WACC.

Investment conviction is medium. Evidence quality is high for filings, cash flow, transaction prices and management guidance; moderate for franchise-level competitive strength; and low-to-moderate for target-company performance, market share and future acquisition returns. The call would improve after two consecutive quarters of at least 5% core growth with at least two points of volume/mix, positive packaging-and-color growth, falling adjustment intensity and pro forma ROIC near 17–18%. It would deteriorate if core growth falls below 3%, PQI volume remains negative after easier comparisons, acquisition-related exclusions become recurrent, or consolidated ROIC falls below 15% without a credible recovery path.

Changes since 2026-07-04

The July thesis correctly identified a recurring-revenue-heavy, low-capex franchise with high cash conversion, approximately 19% standardized ROIC, limited insider-buying support and unresolved PQI weakness. Four items are confirmed. Recurring revenue remained above 60%; Water Quality remained the stronger segment; first-half free cash flow exceeded net income; and standardized trailing ROIC remained far above a reasonable industrial cost of capital. [S1][S2][S11]

Several prior claims are now stale. The former adjusted-EPS estimate of approximately $4.24 has been superseded by guidance of $4.35–$4.43. The absence-of-catalyst framing is weaker because management is forecasting volume-led second-half growth and has initiated a cost program. The description of $2 billion as idle cash is obsolete after more than $1.05 billion of first-half acquisition and repurchase spending, Alfaa UV and the pending $465 million Cleanwater1 transaction. [S2][S3][S5][S9]

Two prior assumptions are materially falsified. First, Veralto is no longer accurately described as nearly GAAP-pure without qualification. Q2 GAAP EPS was $0.98 versus $1.11 adjusted; goodwill rose from $2.838 billion at year-end 2025 to $3.167 billion, and net intangible assets increased from $524 million to $828 million. Some difference is temporary restructuring, but acquisition amortization will persist. Second, the prior description of compensation as a strong returns-based defense against empire building was overstated because qualifying acquisitions of at least $250 million are excluded from adjusted invested capital in the PSU ROIC calculation during the relevant performance period. [S2][S3][S4]

The former blanket oligopoly language is also rejected. Veralto’s filing describes its markets as highly competitive and explicitly identifies low-cost manufacturing, emerging technologies and competitor consolidation. The defensible conclusion is a portfolio of uneven franchise advantages, strongest where installed equipment pulls proprietary consumables and where switching creates operational risk. [S1]

Prior falsifiers remain open. Packaging and color improved sequentially but remained negative. Management still characterizes data-center exposure as small. PFAS remains a long-duration opportunity, but proposed compliance extensions and reconsideration of several compounds weaken a simple near-term regulatory acceleration thesis. Most importantly, the return on the accelerated acquisition program cannot yet be observed. [S2][S12][S19]

Stock Price Action — Five-Year Event Map

Veralto has less than three years of stand-alone history, so a literal five-year company chart does not exist. Company Financials begins the price series on September 27, 2023. The first close was $80.60; the lowest recorded intraday price was $65.51 on October 26, 2023; the all-time intraday high was $115.00 on October 24, 2024; and the September 10, 2026 close was $93.45. The trailing 52-week range was approximately $80.03–$109.86, placing the current price about 46% of the way from the low to the high and 18.7% below the all-time intraday high. Price moves below are facts; causal explanations are interpretations unless explicitly tied to a disclosed event. [S11]

1. September–October 2023: $80.60 to $65.51 intraday, approximately −19%. The separation created a smaller security with no stand-alone public record. Post-spin selling is a plausible explanation, but the filing establishes only the distribution mechanics, not seller motivation. [S1][S11]

2. October 2023–October 2024: $65.51 to $115.00, approximately +76%. Reported execution improved, gross margin expanded and investors obtained evidence of recurring revenue and cash conversion. A quality re-rating is a reasonable interpretation, not a company-supplied attribution. [S1][S11]

3. October 2024–April 2025: $115.00 to roughly $84–$87, approximately −25%. The business continued to grow, so the price decline was much larger than the earnings change. Multiple normalization, tariff uncertainty and reassessment of a mid-single-digit growth rate are plausible drivers. [S1][S11]

4. April–September 2025: roughly $84–$87 to $109.86, approximately +25–30%. Resilient water demand, margin delivery and relief from the April tariff shock plausibly helped. There is no authoritative decomposition separating company execution from broader quality-industrial rotation. [S11][S23]

5. September 2025–May 2026: $109.86 to $80.03, approximately −27%. Q1 disclosed high-single-digit weakness in packaging and color, uneven China municipal demand and a core-growth outlook still dependent on pricing. Those facts support a company-specific explanation, although the factor model explains only 31.4% of return variance and broader effects also mattered. [S2][S12][S23]

6. May–August 19, 2026: $80.03 to $100.10, approximately +25%. Q2 results, raised adjusted-EPS guidance, the 5–6% second-half core-growth forecast and water acquisitions provide a plausible fundamental explanation. The August 19 endpoint coincided with the Cleanwater1 announcement, but event proximity does not prove that the transaction caused the whole move. [S3][S5][S11]

7. August 19–September 10, 2026: $100.10 to $93.45, approximately −6.6%. No new quarterly result was reported. Skepticism about the Cleanwater1 valuation, profit-taking and factor movement are hypotheses; a proper event-study residual is unavailable. [S5][S11][S23]

Verdict. The shares are neither distressed nor near their historic high. The unusually large price moves around a slowly evolving earnings stream show that valuation changes have mattered more than earnings revisions. Future performance is most likely to be determined by whether the forecasted volume acceleration and acquisition returns are verified.

Business Overview

Veralto is a Delaware-incorporated US C-corporation separated from Danaher in September 2023. Its ordinary common shares trade on the NYSE; it is not an ADR, partnership, master limited partnership or K-1 security. It employed approximately 17,000 people at year-end 2025 and reports two segments: Water Quality and Product Quality & Innovation. [S1]

The business is readily understandable at the driver level: equipment and workflows establish a position; consumables, service and software monetize it; price, utilization, retention, mix and productivity determine organic profit growth; and acquisitions add new installed bases at the cost of purchase consideration, goodwill, amortization and execution risk.

The recurring-revenue mechanism

Veralto sells analytical instruments, treatment systems, marking and coding equipment, packaging and color hardware, software, reagents, inks, fluids, spare parts and service. A customer purchases an instrument or coder, incorporates it into a laboratory or production process, trains staff, establishes operating procedures and then buys compatible consumables or service. That creates repeat demand without requiring a contractual subscription.

The recurring label requires precision. Veralto defines recurring revenue as consumables, services, spare parts and operating-type leases; equipment and sales-type leases are nonrecurring. The 2025 10-K states that service and software revenue was immaterial for the disclosed revenue table. Therefore, the recurring base is primarily a consumables-and-parts stream rather than a software subscription model. FY2025 recurring revenue was $3.359 billion, or 61.0% of sales. Q2 2026 recurring revenue was $915 million, or 62.1%; first-half recurring revenue was $1.802 billion, or 62.2%. [S1][S2]

Revenue stability is high relative to most industrial companies, but it is not subscription-like certainty: 62.2% of first-half sales were recurring, while equipment, projects and packaging-and-color capital spending still create quarterly variability. A reagent or ink order can follow usage, but an instrument, municipal treatment installation or color-measurement system can be postponed.

Water Quality

Water Quality generated $3.321 billion of FY2025 sales and $844 million of operating profit, a 25.4% segment margin. Q2 2026 sales were $908 million, approximately 61.6% of consolidated sales, and segment operating profit was $228 million. The segment includes Hach, Trojan Technologies, ChemTreat, OTT HydroMet, McCrometer, In-Situ and Alfaa UV. [S1][S2][S9]

Hach sells laboratory and process instruments, sensors, reagents and standards used to measure water chemistry. Its customer value is not limited to instrument precision. Users need repeatable methods, documentation, training, compatible chemistry and uptime. A method embedded in customer procedures can make an apparently cheaper instrument costly to adopt.

Trojan sells ultraviolet disinfection and related treatment systems. Initial projects are more transactional than Hach reagents and can depend on municipal funding, engineering schedules and permitting. The installed equipment creates replacement-lamp, parts and service potential, but the company does not disclose Trojan aftermarket attach or retention.

ChemTreat supplies industrial water-treatment chemicals and field expertise for cooling, boiler, process and wastewater applications. The chemical is only part of the value: the customer pays for process reliability, dosing knowledge and on-site service. ChemTreat grew core sales 10.7% in Q2, substantially faster than analytics at 2.8%. That is favorable operating evidence but also means the latest Water Quality acceleration was not primarily an analytics story. [S2]

In-Situ expands environmental sensors and monitoring; Alfaa UV expands industrial and commercial UV treatment, particularly in India. These additions broaden product and geographic reach but also increase acquired intangibles and integration requirements. [S6][S9]

Water Quality recurring revenue was $1.966 billion in FY2025, 59.2% of segment sales, and $541 million in Q2 2026, 59.6%. This is a strong mix, but approximately 40% remains equipment or project revenue. [S1][S2]

Product Quality & Innovation

PQI generated $2.182 billion of FY2025 sales and $549 million of operating profit, a 25.2% segment margin. Q2 2026 sales were $566 million and operating profit was $119 million, a 21.0% margin after restructuring and transaction costs. Brands include Videojet, Linx, Esko, X-Rite, Pantone, TraceGains and GlobalVision. [S1][S2][S7][S8]

Videojet and Linx mark products and packages with dates, lot numbers, serialization and other information. The customer is buying reliable line operation and regulatory or traceability compliance. A coder failure can stop the line, while installed printers consume inks and fluids. This is the clearest PQI version of the installed-base model.

Esko supplies packaging-design and prepress workflows. GlobalVision adds packaging-content inspection and quality control. TraceGains connects food-and-beverage formulation, supplier and compliance data. These businesses offer digital cross-selling opportunities, but Veralto does not separately disclose their annual recurring revenue, retention, contribution margins or post-acquisition organic growth.

X-Rite supplies color-measurement hardware and software; Pantone supplies color standards and related intellectual property. These brands matter where standardization reduces disagreement and rework. They are less protected where customers are purchasing generic hardware rather than a workflow or standard.

PQI recurring revenue was $1.393 billion in FY2025, 63.8% of segment sales, and $374 million in Q2 2026, 66.1%. Yet first-half packaging-and-color core sales declined 4.4%. A high recurring percentage does not eliminate the transactional equipment cycle. [S1][S2]

Customers, geography and unrecognized assets

No single customer is disclosed as material. Hach serves more than 149,000 customers, and the group sells across municipal, industrial, pharmaceutical, food, beverage, consumer-products and research markets. Customer dispersion reduces counterparty concentration but does not eliminate correlated end-market weakness.

FY2025 sales were $2.639 billion in North America, $1.241 billion in Western Europe, $1.505 billion in high-growth markets and $118 million in other developed markets—approximately 48%, 23%, 27% and 2%. Foreign exchange and local public funding can therefore move reported results. [S1]

The economically important installed base and customer workflow position are not separately recognized on the balance sheet. Organically created instrument placements, installed coders, customer procedures, application knowledge and service relationships are expensed rather than capitalized. Their value should be inferred from retention, consumable pull-through, price and margins—not assigned an arbitrary asset value.

Verdict. Veralto has a comprehensible, diversified and unusually recurring industrial model. Its best assets are installed workflows rather than factories. The disconfirming evidence is that recurring revenue is mainly consumables and parts, not contracted software, and almost 40% of sales remains transactional.

Industry Dynamics

Veralto does not operate in one homogeneous water industry. It participates in water analytics, environmental monitoring, municipal and industrial treatment, treatment chemicals, marking and coding, packaging workflows, inspection and color management. Market structure must therefore be assessed by profit pool rather than by applying the water label to the entire portfolio. [S1]

Demand is global rather than primarily domestic: North America contributes about 48% of sales, Western Europe about 23%, high-growth markets about 27%, and other developed markets about 2%. High-growth-market designation does not guarantee current growth. Q2 Water Quality core sales in those markets declined 1.5%, demonstrating that China funding, project timing and regional conditions can offset secular demand. [S1][S2]

A precise consolidated addressable-market number is not supportable from authoritative evidence because the businesses overlap only partially with much larger companies. Scale provides a safer boundary: trailing sales were about $9.13 billion for Xylem, $16.84 billion for Ecolab, $8.42 billion for Dover and $4.01 billion for Pentair. Summing those companies would overstate the opportunity because large portions do not compete with Veralto. The evidence supports global profit pools many times the size of each Veralto franchise, not a single calculated market-share denominator. [S13][S14][S15][S16]

Water analytics and environmental monitoring

Analytics economics are attractive where installed instruments pull proprietary reagents, standards and service. Barriers include validated methods, application expertise, product accuracy, distribution and service. Competitors include Xylem’s analytics brands and other global instrumentation companies. Standardized sensors and instruments face more price competition, while critical laboratory or process applications can sustain higher switching costs.

Xylem provides a useful contrast. Its Q2 2026 organic growth was 1.3%, and Company Financials estimates its trailing gross margin at 39.2%, operating margin at 15.5% and ROIC at 7.6%. Xylem’s lower return reflects a different, more project- and equipment-heavy mix plus goodwill from Evoqua; it does not prove Veralto wins every product category. Xylem’s $3.09 billion of Q2 orders rose sharply because of large Water Solutions and Services awards, illustrating both the upside and lumpiness of project exposure. [S13][S17]

Industrial treatment and chemicals

Industrial water treatment creates repeat chemical and service demand, but the field organization is labor-intensive and scale matters. Ecolab is the most relevant public comparison because Nalco Water has global chemistry, service and customer reach. Ecolab’s Q2 organic sales grew 5%, while its standardized trailing ROIC was about 10.8% and EV/EBITDA about 22.4 times. ChemTreat’s 10.7% Q2 core growth is encouraging, but one strong period is not proof of sustained share gains against a larger rival. [S14][S18]

Municipal disinfection and treatment generate long project cycles and aftermarket opportunities. Bids, engineering, construction, funding and permitting create volatility. Cleanwater1 adds on-site hypochlorite generation, solids management and odor-control systems. Its installed base is attractive, but only approximately 25% of sales is aftermarket, leaving the target more transactional than Veralto overall. [S5]

Marking, coding and packaging workflows

Marking and coding has favorable aftermarket economics because inks, fluids, parts and service recur while downtime is costly. Dover’s Markem-Imaje is a credible competitor to Videojet. Dover’s consolidated standardized trailing operating margin was approximately 16.9%, ROIC 10.6% and EV/EBITDA 17.5 times, although consolidated figures do not disclose coding-specific returns. [S15]

Packaging design and inspection can become sticky when integrated into customer processes. Competition nevertheless comes from specialist software, internal tools and AI-assisted entrants. AI may improve Veralto products, but it can also lower some development barriers. Color-measurement hardware remains exposed to capital spending in automotive, textiles and building products.

The industry is profitable where installed equipment pulls proprietary consumables and service, but barriers vary substantially and several capable competitors matter in every major pool. Veralto’s own filing describes highly competitive markets and lists price, quality, performance, delivery, service, application expertise, technology, distribution, breadth and brand among the competitive dimensions. [S1]

Regulation

Water regulation supports durable demand but should not be translated directly into near-term revenue. EPA’s Lead and Copper Rule Improvements require identification and replacement of lead and certain galvanized service lines, generally within ten years subject to exceptions, and require more rigorous testing and inventories. This creates monitoring and infrastructure work, but Veralto does not quantify its direct revenue exposure. [S20]

PFAS timing is less linear. EPA has proposed retaining the 4-parts-per-trillion PFOA and PFOS standards while allowing eligible systems as much as two additional compliance years, potentially to 2031, and reconsidering several other compound standards. Monitoring obligations persist, but treatment project timing may shift. [S19]

Capital-cycle and low-cost-entry lens

The limiting supply-side capital is not primarily factory capacity. More difficult assets include application engineers, installed instruments, validated products, service coverage, methods, customer data and distribution. Physical capex remains modest and there is no evidence of an industry-wide capacity glut.

Financial capital is more concerning. High-quality niche assets are being acquired at mid-to-high-teen EBITDA multiples, sometimes after including prospective synergies. Competitive bidding for scarce targets can transfer much of the future economic surplus to sellers even if the target industry remains attractive. The important capital-cycle risk is acquisition pricing rather than excessive factory construction.

Low-cost foreign production can pressure stand-alone hardware, but it is less capable of displacing businesses protected by qualification, application support, service density and proprietary consumables. The threat is highest in standardized sensors, generic equipment and color hardware; it is lower where process failure is expensive or a method is embedded.

Competitive intensity is stable-to-increasing rather than declining: consolidation strengthens large incumbents, low-cost manufacturers attack hardware, and emerging software and sensor technologies lower selected entry barriers. Veralto’s $266 million of FY2025 R&D, approximately 4.8% of sales, helps defend relevance, but retention and price-volume outcomes are the better tests. [S1]

Verdict. The best profit pools—analytics consumables, marking-and-coding aftermarket and embedded workflows—have attractive economics. Project treatment and standardized hardware are more contestable. Regulation provides a long-duration demand floor rather than a guaranteed near-term acceleration; acquisition pricing is the most concerning part of the current capital cycle.

Competitive Position

A moat claim should identify the mechanism and the observable outcome that would deteriorate if the mechanism disappeared. Veralto’s approximately 60% trailing gross margin, roughly 23% operating margin, cash conversion around 100% and standardized ROIC near 18% are evidence that meaningful parts of the portfolio earn price and retention benefits. They do not establish equal protection across every brand. [S1][S2][S11]

Hach

Hach combines instruments, compatible reagents, method familiarity, application knowledge, documentation and distribution. A municipal or industrial customer changing platforms may need to retrain technicians, validate results, alter procedures, integrate new data and accept process risk. Those costs can exceed the instrument’s price difference.

Water Quality’s 59–60% recurring mix and 25.4% FY2025 segment margin support this mechanism. The disconfirming evidence is limited brand-level disclosure: Veralto does not publish Hach retention, reagent attach, instrument placements or share. Moreover, Q2 analytics core growth of 2.8% lagged ChemTreat. The moat appears real, but current segment acceleration should not be attributed solely to Hach. [S1][S2]

ChemTreat

ChemTreat embeds treatment programs, chemistry and field personnel in customer facilities. Switching can disrupt dosing, cooling or boiler operations. Its 10.7% Q2 core growth and 7.4% first-half growth indicate current relevance. The narrower moat assessment follows from Ecolab’s greater service and chemistry scale and the absence of disclosed customer-cohort data. [S2][S14][S18]

A falsifying signal would be sustained volume loss or price rollback while Ecolab’s corresponding water businesses grow. Without route-density, retention or share data, a conclusion that ChemTreat is structurally winning share would be premature.

Trojan and acquired treatment assets

Trojan benefits from engineering references, validation and an installed aftermarket. Initial projects remain competitively bid and budget dependent. Cleanwater1’s roughly 25,000 installed units could create service and replacement demand, but only 25% of target revenue is currently aftermarket. The investment case depends on increasing attach or generating other margin improvements, not simply counting units. [S5]

In-Situ broadens environmental monitoring, and Alfaa UV adds local capability in India. Both may strengthen channel coverage. In-Situ’s disclosed return depends partly on $11 million of year-three cost synergies; Alfaa’s price and target financials were not disclosed. Strategic adjacency is evidence of fit, not of value creation. [S6][S9]

Videojet and Linx

Videojet and Linx occupy a production-line position where reliability, service and consumable compatibility matter. Changing equipment may require qualification, technician training and planned downtime. The installed printer then consumes inks and fluids. Positive marking-and-coding growth of 3.5% in Q2 amid packaging-and-color weakness supports greater resilience.

Dover’s Markem-Imaje and other global suppliers prevent monopoly characterization. If Videojet’s advantage weakened, expected evidence would include falling consumable growth, price concessions, lost placements or margin erosion. Veralto does not disclose those metrics by brand, so PQI recurring mix and marking-and-coding core growth are the available proxies. [S1][S2][S15]

Esko, GlobalVision, TraceGains, X-Rite and Pantone

Esko and GlobalVision seek to cover packaging workflows from design through content inspection. Their long partnership reduces technical-integration uncertainty. GlobalVision had an expected $25 million revenue base, 85% recurring mix and 30% stand-alone adjusted EBITDA margin at acquisition. Yet the disclosed 15-times multiple was based on estimated EBITDA including year-two cost synergies. Investors should not capitalize the synergies twice. [S7]

TraceGains was expected to generate just over $30 million of revenue, more than 95% recurring revenue, approximately 80% gross margin and growth above 20%. Those are attractive product economics. The $350 million price—about 11.7 times revenue—and year-six double-digit-return objective show that a good product can still be an expensive asset. [S8]

X-Rite and Pantone matter through standardization, measurement accuracy and workflow familiarity. Brand relevance is economic only if it reduces perceived process risk, preserves compatibility or influences workflow choice; recognition without retention or pricing is not a moat.

Competition, switching costs and VES

Competition is multi-dimensional: price matters, but uptime, service, application expertise, technology, delivery and installed compatibility matter more in the strongest franchises. Standardized products face price competition; validated applications and production-critical installations favor incumbents. [S1]

Switching can require retraining, requalification, process disruption and replacement of consumables or software workflows, although those costs range from substantial in validated applications to modest in standardized hardware. A portfolio-wide switching-cost label would therefore be misleading.

The Veralto Enterprise System is an operating, commercial, innovation and acquisition toolkit derived from the Danaher Business System. VES can improve pricing, working capital, product development and integration. It is not itself a barrier to entry because competitors can implement lean processes. Its value is observable only when organic growth, margins, cash conversion and acquisition returns improve.

The investor-day material refers to more than 80 inherited acquisitions and attractive historic returns, but that record largely predates Veralto’s stand-alone governance. Moreover, company materials do not use a perfectly consistent written formula for acquisition ROIC. The measure is non-GAAP and differs from standardized consolidated ROIC; investors need actual acquired-business profit and capital data rather than a slogan. [S5][S10]

Verdict. Veralto has a real but uneven moat. Hach and Videojet offer the clearest installed-base and consumable mechanisms; Esko and Pantone have narrower workflow or standards advantages; ChemTreat relies more on service execution; and treatment projects are more contestable. High consolidated returns validate the portfolio, while the company’s own competition disclosure and limited brand metrics constrain a wider claim.

Growth History and Forward Opportunities

Reported revenue increased from $4.870 billion in 2022 to $5.021 billion in 2023, $5.193 billion in 2024 and $5.503 billion in 2025, a three-year compound rate of approximately 4.2%. Operating profit rose from $1.112 billion to $1.277 billion, approximately 4.7% annually, while gross margin expanded from 56.7% to 60.0%. GAAP diluted EPS increased from $3.43 to $3.76, approximately 3.1% annually. The historical record is a mid-single-digit revenue and operating-profit compounder, not a high-single-digit organic grower. [S1][S11]

First-half 2026 reported sales rose 7.1%, but acquisitions contributed 1.8 points and foreign exchange 2.2 points. Core growth was 3.1%, including approximately 2.4 points of price and only 0.7 points of implied volume/mix. Q2 improved: reported growth was 7.6%, core growth 4.2%, price 3.0 points and implied volume/mix 1.2 points. [S2]

The product outlook is favorable but not yet proven to have changed the growth algorithm: management expects 5–6% second-half core growth led by volume, whereas first-half core growth was 3.1% and predominantly price. Management’s confidence rests on industrial water, marking and coding, digital workflows, easier comparisons and funnel improvement. [S3][S12]

The mix matters. Q2 Water Quality core growth of 5.7% included approximately 2.8 points of implied volume/mix, but PQI’s 2.0% core growth against 3.0 points of price implies roughly negative 1 point of volume/mix. First-half PQI core growth was only 0.5%, while packaging and color declined 4.4%. Volume acceleration was therefore segment-specific rather than broad.

Water opportunities

Industrial water is the strongest disclosed demand area. Management has cited data centers, power, mining and semiconductors and reported high growth at ChemTreat. Management also described data-center exposure as small at the Veralto level. Data-center water should therefore be treated as an option until the company quantifies orders, revenue, installed content and recurring pull-through. [S12]

Water reuse requires disinfection, monitoring and process control and therefore supports Trojan and Hach-related demand. Municipal demand has been described as steady. The Lead and Copper rule adds long-duration testing and infrastructure needs; PFAS timing is more uncertain. The base case should assume ordinary mid-single-digit water growth rather than a sudden regulatory step-up. [S19][S20]

In-Situ was expected to generate approximately $80 million of 2025 sales, around 50% gross margin, a mid-teens EBITDA margin and high-single-digit historical growth. The $11 million year-three cost-synergy target is material relative to the target’s starting EBITDA, making integration important to the underwritten return. [S6]

Alfaa UV adds products and local manufacturing in India but lacks disclosed price or target financials. Cleanwater1 adds approximately $135 million of trailing sales, low-double-digit growth since 2023 and an installed base of about 25,000 units. Increasing the 25% aftermarket mix could improve recurring revenue; failure to do so would leave Veralto with a project-heavier business acquired at about 3.4 times sales. [S5][S9]

PQI opportunities

Marking and coding should benefit from packaged-goods production, SKU proliferation and traceability. It is more likely to compound at a GDP-plus rate than to become a sustained high-single-digit grower without share gains.

Packaging and color could recover as customers resume deferred purchases. Management noted better funnels and easier comparisons, but that is a claim. Four more quarters of negative growth despite easier comparisons would suggest structural weakness rather than ordinary timing.

TraceGains and GlobalVision offer faster digital growth from small bases and potential cross-selling across Esko, food, pharmaceutical and consumer-goods relationships. Veralto does not disclose acquired-company organic revenue, retention or contribution margin, so these assets should be modeled as options until reported results demonstrate consolidated impact.

Cost program and per-share growth

The 2026 Cost Optimization Program includes workforce reductions, site consolidation and functional transformation. Expected charges are $85–$105 million, with completion substantially by 2028. Management indicated that only a few million dollars of benefit was expected in Q4 2026, with more benefit in 2027 and 2028, but the final savings target has not been disclosed. [S2][S12]

Restructuring can improve the cost base, but it is not organic demand. Repurchases can lift EPS while total profit grows more slowly. The sustainable algorithm is approximately 4–5% organic growth, modest margin expansion, acquired growth and limited net share reduction. A durable 6% core-growth outcome requires reported unit evidence.

Verdict. Veralto has credible growth vectors in industrial water, monitoring, reuse and digital packaging workflows. None is yet disclosed at sufficient scale to demonstrate a consolidated growth regime above mid-single digits. The near-term test is the promised volume-led acceleration; the longer-term test is whether acquired assets expand recurring revenue and profit faster than invested capital.

Financial Quality

Multi-year income statement

The table combines carve-out and stand-alone history reconciled between filings and Company Financials. Gross margin expanded materially, consistent with price, mix and productivity. Operating margin did not expand proportionately because selling, administration, R&D, transactions and restructuring absorbed part of the benefit. [S1][S2][S11]

Q2 2026 sales were $1.474 billion, gross profit $902 million and operating profit $315 million. Gross margin reached 61.2%, while GAAP operating margin fell to 21.4%. Adjusted operating margin was 24.6%, but a $16 million tariff recovery added approximately 110 basis points. An economically neutral comparison should exclude both restructuring charges and unusual tariff recoveries rather than accepting only favorable adjustments. [S2][S3]

Earnings are near neither a classical cyclical peak nor a trough: recurring demand supports the base, gross margin is at a multi-year high, PQI equipment demand is weak, and restructuring depresses reported operating margin. This mixed-cycle condition argues against capitalizing either current gross margin or current PQI weakness as permanent.

GAAP, adjusted earnings and accounting quality

FY2025 GAAP diluted EPS was $3.76 versus approximately $3.90 adjusted, a modest gap. Q2 2026 GAAP EPS of $0.98 was adjusted to $1.11, a $0.13 or 13% uplift relative to GAAP EPS. The adjustments principally reflected acquisition-related amortization, restructuring, transaction items and tax effects. [S3]

Amortization is noncash but not costless: the intangible assets were purchased with cash or debt. Restructuring can be excluded when estimating a post-program run rate, but repeated programs would make exclusion less defensible. The tariff recovery should not be annualized, and management did not assume additional material recoveries in guidance. [S3][S12]

Accounting remains cash-backed and conventional, but the widening acquisition-amortization and restructuring bridge means the former nearly-GAAP-pure characterization is no longer sufficient. Goodwill increased by $329 million and net intangibles by $304 million during the first half. The bridge may narrow after restructuring, but amortization is likely to rise further after Cleanwater1.

No material revenue-recognition, inventory or capitalization-policy change was identified in the 2026 10-Q. The filing discusses future expense-disaggregation requirements, but those are disclosure changes rather than a cause of operating performance. [S1][S2]

Cash flow and capital intensity

FY2025 operating cash flow was $1.077 billion, capex $63 million and free cash flow $1.014 billion, equal to 108% of net income. First-half 2026 operating cash flow was $522 million, capex $24 million and free cash flow $498 million, versus $495 million of net income. Q2 alone produced $340 million of operating cash and $328 million of free cash flow. [S1][S2][S3]

Operating cash flow continues to track at or above net income over full-year and first-half periods, with short-term differences caused primarily by amortization, stock compensation and ordinary working-capital movements. Receivables, inventory and prepaid assets consumed some first-half cash; there is no evidence of chronic receivables growth propping up reported earnings.

Capital expenditure remains close to 1% of sales, making the operating business low-capital-intensity; acquisitions, not factories, are the dominant reinvestment requirement. Annual capex was $34 million in 2022 and $54–$63 million in 2023–2025. Low capex supports cash conversion, but reported free cash flow can overstate owner earnings if acquisitions are required to sustain the desired growth rate. [S1][S11]

Return on invested capital

Company Financials estimates standardized trailing ROIC at approximately 18.0% for Q2 2026, down from 18.8% for FY2025 and 19.7% at Q1. Definitions can vary, but the trend is consistent with acquired goodwill and intangibles entering invested capital before full earnings contribution. [S11]

Reported standardized ROIC is approximately 18%, materially above peer estimates for Xylem, Ecolab, Dover and Pentair, but it has declined as acquired capital increased and must be monitored on a pro forma basis. Peer estimates are approximately 7.6%, 10.8%, 10.6% and 13.1%, respectively. [S13][S14][S15][S16]

Veralto’s announced acquisition-return objectives are not the same as consolidated accounting ROIC. They use management-defined adjusted profit and acquisition-price measures and may include synergies. Written descriptions of the formula are not perfectly consistent across company materials, so the targets should be treated directionally. The relevant shareholder test is after-tax cash profit divided by all capital committed, including integration costs.

Balance sheet and obligations

At July 3, 2026, cash was $2.119 billion, current debt $700 million and long-term debt $2.679 billion. The $3.379 billion total included $725 million of new 4.85% notes due 2032 issued before the $700 million notes due September 18, 2026 were repaid. Paying the maturity reduces cash and debt by similar amounts; it does not materially change normalized net debt. The company reported no revolver or commercial-paper borrowings. [S2][S21]

Using quarter-end figures, net debt was approximately $1.26 billion, or about 0.9 times trailing EBITDA. After the maturity and assuming the pending $465 million Cleanwater1 purchase is cash-funded, pro forma net debt could approach $1.7 billion before subsequent cash generation, roughly 1.2 times trailing EBITDA. That is an estimate, not reported leverage, and remains manageable.

Operating leases are recorded on balance sheet, while pending Cleanwater1 consideration is a real economic commitment that was not a July 3 liability because the transaction had not closed. Operating-lease liabilities were approximately $204 million. Warranty reserves were $29 million and deferred-compensation liabilities were about $52 million at quarter-end. [S2][S5]

Separation-related tax and indemnity arrangements, litigation and warranties remain contingent risks. None disclosed is comparable in scale to funded debt or the pending acquisition. Cash was roughly evenly split between US and foreign locations, with $1.004 billion in the US and $1.115 billion outside the US, which can affect deployment flexibility and taxes. [S2]

Verdict. Financial quality remains high: rising gross margin, low capex, cash conversion around 100%, manageable leverage and standardized ROIC above peers. Disconfirming evidence is the declining recent ROIC, larger acquired-intangible base and a wider quarterly GAAP-to-adjusted bridge.

Capital Allocation

Veralto states that it prioritizes internal reinvestment, strategic acquisitions, a growing dividend and opportunistic repurchases while maintaining an investment-grade profile. The stand-alone record increasingly reflects an acquisition-led strategy combined with meaningful buybacks. [S1][S4][S10]

Free cash flow generation is approximately $1 billion annually, and management deploys it among internal investment, acquisitions, repurchases and a modest dividend; first-half 2026 deployment materially exceeded current-period free cash flow and used accumulated liquidity plus debt-prefunding cash. First-half acquisitions, repurchases and dividends totaled approximately $1.118 billion against $498 million of FCF. [S2]

Acquisition scorecard

Sources: [S5][S6][S7][S8][S9].

The significant acquisitions are strategically coherent, but realized returns are not publicly observable and three-to-six-year hurdle periods show that the purchase prices require sustained growth, margin expansion or synergies. Veralto does not publish an acquired-business scorecard comparing sales, margin and ROIC with original underwriting.

Cleanwater1 is the clearest current test. Dividing the $452 million tax-adjusted price by the stated 17-times multiple implies approximately $26.6 million of trailing adjusted EBITDA and a margin near 19.7%. Target financials were supplied by target management, are unaudited and have not been conformed fully to Veralto’s accounting policies. The release’s written ROIC formula is also internally awkward. The reliable facts are the price, management-adjusted EBITDA multiple and year-four hurdle; realized economic return remains unknown. [S5]

An acquisition expected only to reach WACC several years after closing should be treated as potential value preservation before evidence of value creation. Strategic options can produce upside, but they do not remove the opportunity cost of capital.

Repurchases, issuance and insiders

The board authorized $750 million of repurchases in November 2025. Veralto spent $300 million for approximately 3.2 million shares in Q1 and $434 million for about 5.0 million shares in the first half, implying an average first-half cost around $86.80 including the disclosed aggregate spending. At July 3, $317 million remained authorized. [S2][S6][S7]

First-half repurchases reduced diluted weighted-average shares from 250.0 million to 247.5 million despite $40 million of stock-compensation expense, so the program created a real net share-count benefit. Q2 diluted shares were 245.8 million versus 249.9 million a year earlier, and period-end shares were approximately 244.2 million. [S2]

Stock compensation is meaningful but not excessive relative to cash flow: first-half expense was $40 million, while diluted shares still declined by approximately 1%. Weighted-average and period-end shares answer different questions, but both indicate net retirement.

The reviewed ownership filings do not provide a positive open-market-purchase signal. The July 2026 CEO Form 4 records the exercise of 7,097 options at $28.76 and sale of the same number of shares near $95 under a Rule 10b5-1 plan adopted in February. That is neither a discretionary purchase nor proof of a negative view. A categorical claim about every filing would require a separately reconstructed ownership database, so the defensible conclusion is absence of affirmative insider-buy evidence in the reviewed record. [S22]

Dividend

The quarterly dividend is $0.13 per share, or $0.52 annualized. At $93.45, the yield is approximately 0.56%. Dividends were $109 million in FY2025 and $64 million in the first half of 2026. The annualized payment represents about 12% of the adjusted-EPS guidance midpoint and a small portion of normalized FCF. [S1][S2][S11]

The dividend consumes a small minority of free cash flow and is amply covered; its purpose is a growing baseline distribution while preserving acquisition capacity, not providing high current income.

Governance and compensation

Enterprise leaders’ annual incentives are 70% company financial performance and 30% personal objectives. The company component is 40% adjusted EPS, 40% core revenue growth and 20% free-cash-flow conversion. Long-term awards include performance stock units, options and restricted stock, with PSUs driven mainly by relative TSR and modified plus or minus 10% by a three-year average ROIC-change measure. [S4]

Management compensation emphasizes adjusted EPS, core growth, cash conversion and relative TSR, while ROIC is only a modest modifier and qualifying acquisitions of at least $250 million are excluded from adjusted invested capital during the performance period. This design is a weaker check on expensive large deals than the metric labels imply.

A transaction can improve adjusted EPS through financing, exclusions, acquired profit and synergies while lowering all-in ROIC. The exclusions mean shareholders should not rely on compensation design as a substitute for monitoring goodwill, consolidated returns and cash profit.

Management behavior implies confidence in VES-enabled acquisitions and willingness to accept multi-year paybacks, while limited affirmative insider-buy evidence and the acquisition exclusion in compensation reduce evidence of owner-like downside alignment. That is not proof of poor motivation; it means realized returns deserve more weight than stated discipline.

Verdict. Repurchases produced net share reduction at a reasonable average price, the dividend is conservative and leverage remains manageable. The acquisition program is strategically consistent but economically unproven. Incentive alignment is materially weaker than the prior report claimed because large qualifying acquisitions can be excluded from the invested-capital measure.

Changes and Headwinds — Last Two Years

Results are driven by both the external environment and internal actions: demand determines unit growth, while price, VES productivity, restructuring, acquisitions, tax, financing and repurchases materially influence earnings per share. First-half 2026 illustrates the mix—core sales were price-heavy, yet margin actions and lower shares supported faster adjusted-EPS growth. [S2][S3]

The business environment changed materially through accelerated acquisitions, tariff management, softer packaging-and-color equipment, uneven China municipal funding and an evolving PFAS timetable. The largest strategic shift was from post-spin deleveraging and cash accumulation toward simultaneous M&A and repurchases.

TraceGains was acquired in 2024. In-Situ and GlobalVision closed in 2026, Alfaa UV followed in July, and Cleanwater1 is expected to close in Q4. The portfolio is moving toward environmental monitoring, treatment and digital packaging workflows. These additions diversify products but increase goodwill, amortization and integration risk. [S5][S6][S7][S8][S9]

Tariffs remain a price-cost and supply-chain issue. Veralto relocated production, altered sourcing and used pricing. Q2 included a $16 million IEEPA-related recovery worth approximately $0.05 per share. Because it was unusual and not assumed to repeat materially, it should be removed from a sustainable margin estimate. [S3][S12]

Packaging and color remained the main operating weakness. First-half core sales fell 4.4%; Q2’s 1.4% decline was sequentially better but still negative. Marking and coding remained positive. Water Quality was stronger in North America and industrial applications, while high-growth-market Water Quality declined in Q2 and China municipal funding remained uneven. [S2][S12]

The cost program includes workforce actions, site consolidation and functional transformation, with $85–$105 million of expected charges and substantial completion by 2028. PQI bears most of the charges. Savings have not been quantified, so investors cannot yet calculate payback or distinguish structural productivity from remediation of weak demand. [S2]

No material accounting-policy change explains the operating trend; the larger GAAP-to-adjusted bridge reflects acquisitions, amortization, restructuring and tariff items rather than a new recognition policy. Future expense-disaggregation rules may improve disclosure but do not change economics.

Important changes in markets, facilities and management consist of stronger industrial-water demand, weak packaging-and-color equipment, site consolidation, added Indian UV capability and stable senior leadership. Jennifer Honeycutt remains CEO and Sameer Ralhan CFO. The company also issued $725 million of 4.85% notes due 2032 to refinance near-term debt and maintain flexibility. [S4][S9][S21]

Regulation became less straightforward. Lead-service-line rules support long-term measurement and replacement demand. PFAS monitoring continues, but proposed compliance extensions and reconsideration of some standards may delay treatment spending. [S19][S20]

Verdict. Operating quality has remained resilient, but the risk mix changed. Post-spin financing is no longer the main issue; acquisition underwriting, PQI recovery and cost-program execution are now more important.

Risk Analysis

The principal stock-decline paths are sub-3% core growth, persistent negative PQI volume, acquisition returns near rather than above WACC, a widening adjustment bridge or quality-multiple compression. None requires insolvency or permanent franchise destruction.

The strongest bear counterargument is that adjusted-EPS growth is increasingly supported by price, exclusions and repurchases. First-half implied volume was modest, PQI volume/mix was negative, tax and deleveraging tailwinds are less powerful than immediately after the spin, and acquisitions carry premium prices. If underlying growth settles around 3%, the valuation can compress even while nominal EPS grows.

A catastrophic investment loss would most plausibly require franchise erosion combined with serial acquisition overpayment, rising leverage, impairments and a collapse in confidence in adjusted earnings. A severe product, cyber, regulatory or compliance failure could accelerate that path because customers buy trust and uptime. Diversification, recurring revenue and strong cash generation provide offsets.

A total loss is remote rather than impossible: it would require fraud, extreme debt-funded acquisitions, systemic product liabilities or destruction of several independent franchises, none of which is visible in current evidence. The current balance sheet and approximately $1 billion annual FCF capacity make ordinary cyclicality an implausible total-loss mechanism.

Verdict. Operating-catastrophe risk is low, but valuation and capital-allocation risk are material. The most plausible adverse outcome is several years of mediocre shareholder returns because investors paid a quality multiple while acquired returns drifted toward WACC.

Valuation Discussion

Current multiples

The September 10, 2026 close was $93.45. Applying approximately 244.2 million quarter-end shares produces an equity value near $22.8 billion. Company Financials reported a June 30 enterprise value of approximately $22.9 billion at $88.68 per share, with trailing EV/EBITDA of 16.5 times, P/E of 22.2 times and price-to-FCF of 21.1 times. Updating only the equity value for the subsequent price move produces an estimated enterprise value near $24.1 billion and EV/EBITDA near 17.3 times. The estimate does not capture post-quarter cash flow, the September maturity payment or the Cleanwater1 close. [S2][S11]

The $4.39 midpoint of 2026 adjusted-EPS guidance implies a forward multiple of approximately 21.3 times. Trailing GAAP EPS of about $3.97 implies approximately 23.6 times. Trailing FCF of roughly $1.05 billion implies a 4.5–4.6% equity FCF yield at the updated market value. [S3][S11]

At $85, the same guidance midpoint would imply approximately 19.4 times adjusted EPS and the trailing FCF yield would exceed 5%, providing more protection against slower growth. That entry framing belongs to the opening recommendation; it is presented here only to connect valuation sensitivity with the stated decision threshold.

Peer comparison

Sources: [S11][S13][S14][S15][S16]. Definitions are standardized estimates and may differ from management calculations.

The comparison supports a premium to Pentair and Xylem on enterprise value because Veralto has higher gross margins, recurring mix and standardized ROIC. Ecolab demonstrates the valuation available to a scaled service-and-water franchise but is too expensive to serve as a base-case destination. Dover trades near Veralto’s updated EBITDA multiple despite lower consolidated returns, reducing the argument that Veralto is uniquely expensive.

Peer limitations matter. Xylem is more project- and equipment-heavy; Ecolab includes cleaning and institutional businesses; Dover contains unrelated industrial assets; Pentair has residential and pool exposure. The group establishes boundaries rather than a mechanically precise relative value.

Embedded expectations

The current price appears to embed:

• Approximately 4–5% sustainable core revenue growth rather than the first-half 3.1% rate or a sustained 6–7% rate.
• Pricing normalizing toward 1–2% after tariff-related actions.
• Modest normalized margin expansion after restructuring, without repeating the Q2 tariff recovery.
• Acquisition contribution sufficient to offset financing, amortization and integration costs.
• Continued but slower net share reduction.
• Long-run consolidated returns materially above WACC.

The market correctly recognizes recurring demand, strong margins, low capex and manageable leverage. It is also right not to assign a hypergrowth multiple: three-year revenue CAGR is approximately 4.2%, and first-half organic growth remained price-heavy.

The fragile bull assumption is that management’s second-half volume acceleration becomes durable. The fragile bear assumption is that recent acquisitions necessarily destroy value. The current evidence proves neither. What is observable is that the buyer paid demanding multiples and accepted long periods before reaching disclosed return thresholds.

Scenario framework

These are analyst estimates, not guidance. The bear case assumes quality persists but the premium compresses. The base case requires most of management’s volume and integration objectives. The bull case requires measured growth above Veralto’s history and cannot be justified by the water theme alone.

A DCF cross-check begins with roughly $1.05 billion of trailing FCF. Five-year growth of 7–8%, a 3% terminal rate and an 8–8.5% discount rate support equity value in the low $100s after pro forma net debt. Four-percent growth and a 9% discount rate push value toward the low $80s; 10% growth and an 8% rate support the $120s. Acquisitions complicate the exercise because reported FCF excludes purchase consideration while the growth assumption may depend on acquired businesses.

Adjusted EPS should never be the sole valuation basis. At a 21-times multiple, every recurring $0.10 exclusion represents more than $2 per share. The valuation must be cross-checked against GAAP cash flow, goodwill growth and consolidated ROIC.

Verdict. The shares are fairly valued for a durable mid-single-digit compounder. The current price offers moderate upside if volume and integration deliver, but limited protection if growth remains price-led or returns drift toward WACC.

Variant Perception

The thoughtful investor questions are now whether core growth is becoming volume-led, whether packaging-and-color weakness is cyclical, whether adjusted earnings remain economically comparable with GAAP results, and whether acquisitions bought at demanding multiples can preserve approximately 18% corporate ROIC.

Consensus

The likely consensus is that Veralto is a defensive, Danaher-derived compounder with strong installed bases, mid-single-digit organic growth and high cash conversion. The current multiple indicates that investors recognize the quality but do not assign an Ecolab-like valuation without faster growth. This consensus is broadly reasonable.

Strongest bull case

The bull argues that first-half weakness is backward-looking. Water Quality has positive volume/mix, ChemTreat is growing rapidly, industrial water applications are expanding, marking and coding remains positive, and management forecasts 5–6% second-half core growth led by volume. Restructuring benefits should increase in 2027–2028, repurchases reduced shares, and acquired monitoring, treatment and digital assets broaden the addressable workflow.

If consolidated core growth reaches 6%, PQI turns positive, adjusted margins rise excluding refunds and standardized ROIC remains near 18%, Veralto could sustain low-double-digit per-share growth and merit a higher quality multiple.

Strongest bear case

The bear argues that the company remains a roughly 4% historical grower whose first-half volume was below 1%. PQI’s implied volume/mix remained negative in Q2, analytics grew much more slowly than ChemTreat, and the Q2 adjusted result benefited from a tariff recovery. Acquisitions introduce amortization and restructuring while demanding three-to-six years to reach announced return thresholds.

The compensation framework does not fully counter this risk: the ROIC modifier is small, and qualifying acquisitions of at least $250 million are excluded from adjusted invested capital during the performance period. A sequence of EPS-accretive but low-return deals could therefore be rewarded before shareholders can observe diluted all-in returns. [S4]

Load-bearing assumptions and falsifiers

1. Core growth becomes volume-led. Confirm with two quarters of at least 5% core growth and at least two points of volume/mix. Falsify with core growth below 3% or price accounting for almost all growth.
2. PQI weakness is cyclical. Confirm with positive packaging-and-color growth and PQI margin recovery. Falsify with four additional quarters of negative growth despite easier comparisons.
3. Acquisitions preserve excess returns. Confirm with consolidated ROIC near 17–18%, disclosed synergy delivery and target profit growth. Falsify with ROIC below 15%, impairments or repeated integration restructuring.
4. Recurring revenue supports price without attrition. Confirm with positive volume and stable gross margin as pricing normalizes. Falsify with price rollback, weaker consumable growth or lost placements.
5. Adjusted EPS remains economically real. Confirm with FCF conversion near 100% and declining exclusions. Falsify with adjustments persistently above 15% of GAAP profit or weak cash conversion.

Factor context

The factor model dated September 10 estimates a market exposure of 0.840, Growth exposure of −0.334, InterestRate exposure of −0.270, CreditRisk exposure of +0.261, NewValue exposure of +0.228, LowVolatility exposure of +0.128 and Quality exposure of +0.124. Residual momentum was −0.045, residual Sharpe −0.582 and residual volatility 0.197. The model explains only 31.4% of variance. [S23]

These coefficients are correlations, not causal business facts. Sector coefficients do not change Veralto’s legal industry classification, and the InterestRate coefficient should not be translated into a rate forecast without the factor’s precise construction. The useful conclusions are limited: beta has been below one, the tape has behaved unlike conventional growth momentum, and most share-price variance remains unexplained by the model.

Verdict. The differentiated bullish view is not that the market missed Veralto’s quality; the quality is recognized. It is that management may deliver broad volume acceleration before the multiple reflects it. The differentiated bearish view is that premium-priced acquisitions and adjustment growth will gradually dilute returns. Both remain open, making the next operating and acquisition disclosures unusually informative.

Fact vs. Interpretation

Verdict. Reported financial quality is strong. The least certain and most valuation-sensitive claims concern future volume, franchise-level share and realized acquisition returns.

Open Questions

1. How many points of Q3 and Q4 core growth come from price, volume and mix by segment?
2. Does packaging and color return to positive core growth, and does PQI margin recover after separating restructuring and transaction expenses?
3. What is the gross and net savings target for the $85–$105 million cost program, and how much will be reinvested?
4. How much of Cleanwater1’s 25% aftermarket revenue consists of proprietary consumables, service and parts?
5. What target-company revenue, margin and ROIC are TraceGains, In-Situ and GlobalVision producing relative to underwriting?
6. How will management reconcile the written acquisition-ROIC formula with actual after-tax cash returns?
7. Will the remaining repurchase authorization be used after Cleanwater1, or will leverage reduction take priority?
8. Are high-growth-market Water Quality declines project timing or competitive share pressure?
9. What revenue is directly attributable to data centers, PFAS monitoring and reuse rather than merely associated with those themes?
10. Can recurring revenue remain above 62% after adding a target with only 25% aftermarket sales?
11. Will acquisition-related amortization and restructuring fall below 10% of GAAP earnings after 2027?
12. Will compensation disclosure eventually include an all-in ROIC measure that does not exclude large acquisitions?

What Must Be True

Bull tests

• Core growth must average at least 5% over the next four quarters, with volume and mix contributing at least two points. Price-only growth does not satisfy the test.
• Water Quality must sustain mid-single-digit growth while PQI packaging and color turns positive by the first half of 2027.
• Adjusted operating margin must improve after excluding tariff recoveries, and FCF conversion must remain near 100%.
• Consolidated standardized ROIC must remain above roughly 17% after In-Situ, GlobalVision, Alfaa UV and Cleanwater1 are fully reflected.
• Cleanwater1 aftermarket mix must increase, or disclosed margin and growth must otherwise justify its purchase price.
• Diluted shares must continue to decline without pro forma leverage rising materially above approximately 1.5 times EBITDA.

Bull falsifiers: two quarters below 3% core growth; packaging and color remaining negative after easier comparisons; consolidated ROIC below 15%; an impairment; recurring exclusions above 15% of GAAP profit; or net debt above two times EBITDA without a commensurate increase in cash earnings.

Bear tests

• The bear case requires management’s volume-led forecast to fail, leaving organic growth around 3% or less.
• PQI weakness must persist beyond an ordinary equipment cycle, with marking and coding also slowing.
• Acquisition synergies must arrive slowly enough that consolidated ROIC trends toward WACC.
• Adjusted-EPS growth must increasingly exceed GAAP profit and cash-flow growth.
• The market must value Veralto more like a conventional industrial after evidence that the quality premium is not producing excess growth.

Bear falsifiers: at least two quarters of 6% core growth led by volume; positive packaging-and-color growth with PQI margin recovering toward 25%; acquired-business performance disclosed above original cases; consolidated ROIC remaining near 18% after Cleanwater1; and GAAP EPS converging with adjusted EPS.

The decision sequence is measurable. Q3 tests the volume forecast. Q4 and the Cleanwater1 close test recurring mix and pro forma leverage. 2027 tests cost-program savings and integration. The thesis should be upgraded only on reported volume, transparent acquired-business performance and excess returns—not on additional thematic announcements. [S2][S3][S5][S12]

Public source appendix

• S1: Veralto Corporation 2025 Form 10-K — SEC primary filing; published 2026-02-20; Items 1, 1A, 7 and 8; segment results; revenue disaggregation; Notes 2, 4, 7, 9, 12, 16 and 17
• S2: Veralto Corporation Q2 2026 Form 10-Q — SEC primary filing; published 2026-07-29; Financial statements; Notes 2, 4, 8, 9, 11 and 12; MD&A core-sales, segment, restructuring and repurchase tables
• S3: Veralto Q2 2026 earnings release and non-GAAP reconciliation — Company primary release; published 2026-07-28; Pages 1–9; results, guidance, cash flow, segment margins, tariff recovery and EPS reconciliation
• S4: Veralto 2026 proxy statement — SEC primary filing; published 2026-03-27; Executive compensation; annual incentive metrics; PSU design; ROIC modifier; adjusted invested-capital definition and acquisition exclusions
• S5: Veralto agreement to acquire Cleanwater1 — Company primary release; published 2026-08-19; Purchase price, target sales, aftermarket mix, installed base, EBITDA multiple, accounting qualifications and year-four return objective
• S6: Veralto agreement to acquire In-Situ and establish repurchase program — Company primary release; published 2025-11-25; Purchase price, sales, margins, synergies, valuation, return objective and repurchase authorization
• S7: Veralto acquisition of GlobalVision and repurchase update — Company primary release; published 2026-03-31; Sales, recurring mix, stand-alone margin, synergy-inclusive valuation, return objective and Q1 repurchases
• S8: Veralto acquisition of TraceGains — Company primary release; published 2024-10-07; Purchase price, expected sales, recurring mix, gross margin, growth and year-six return objective
• S9: Veralto acquisition of Alfaa UV — Company primary release; published 2026-07-21; Products, geography, applications and integration into Trojan Technologies
• S10: Veralto Investor and Analyst Day presentation — Company primary presentation; published 2023-09-06; Business model, recurring mix, portfolio-selection criteria, VES and acquisition-return framework
• S11: Company Financials — VLTO statements, ratios, valuation and market history — Company Financials data reconciled to filings; published 2026-09-10; Annual 2022–2025 and quarterly through Q2 2026 statements; profitability; ROIC; enterprise value; valuation; daily OHLC through 2026-09-10
• S12: Company Financials — Veralto Q1 and Q2 2026 earnings-call transcripts — Company Financials transcript; published 2026-07-29; Calls dated 2026-04-29 and 2026-07-29; management commentary on volume, pricing, PQI, tariffs, cost program, China, acquisitions and data centers
• S13: Company Financials — Xylem Q2 2026 peer snapshot — Company Financials peer data reconciled to filing; published 2026-06-30; Trailing profitability, ROIC, enterprise value and valuation multiples through 2026-06-30
• S14: Company Financials — Ecolab Q2 2026 peer snapshot — Company Financials peer data reconciled to filing; published 2026-06-30; Trailing profitability, ROIC, enterprise value and valuation multiples through 2026-06-30
• S15: Company Financials — Dover Q2 2026 peer snapshot — Company Financials peer data reconciled to filing; published 2026-06-30; Trailing profitability, ROIC, enterprise value and valuation multiples through 2026-06-30
• S16: Company Financials — Pentair Q2 2026 peer snapshot — Company Financials peer data reconciled to filing; published 2026-06-30; Trailing profitability, ROIC, enterprise value and valuation multiples through 2026-06-30
• S17: Xylem Q2 2026 Form 10-Q — SEC peer primary filing; published 2026-07-28; Financial statements and MD&A; organic growth, orders and segment demand
• S18: Ecolab Q2 2026 Form 10-Q — SEC peer primary filing; published 2026-08-06; Financial statements, organic sales, segment results and capital structure
• S19: US EPA proposed PFOA and PFOS compliance-extension rule — Regulator primary source; published 2026-05-18; Retention of PFOA/PFOS standards, possible two-year extension and reconsideration of other compound standards
• S20: US EPA Lead and Copper Rule Improvements — Regulator primary source; published 2025-12-29; Final-rule requirements for inventories, testing, communication and lead-service-line replacement
• S21: Veralto 4.85% senior notes due 2032 filing — SEC primary filing; published 2026-06-01; $725 million principal, coupon, issuance proceeds, permitted uses and maturity
• S22: Veralto CEO Form 4 dated July 2026 — SEC ownership filing; published 2026-07-21; Option exercise, simultaneous sale and Rule 10b5-1 transaction-plan indicator
• S23: The factor model — VLTO statistical exposure snapshot — Internal quantitative diagnostic; published 2026-09-10; Factor exposures, residual signals and diagnostics dated 2026-09-10